AstraZeneca (NASDAQ: AZN) reported Q2 EPS of $2.63, $0.14 better than the analyst estimate of $2.49. Revenue for the quarter came in at $15.38 billion versus the consensus estimate of $15.47 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.